Loading clinical trials...
Loading clinical trials...
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Conditions
Interventions
Inlexisertib
Ripretinib
Locations
24
United States
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Massachusetts Worcester
Worcester, Massachusetts, United States
START Midwest
Grand Rapids, Michigan, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
Start Date
September 28, 2023
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2029
Last Updated
April 16, 2026
NCT03594422
NCT03050268
NCT06655246
NCT06441331
NCT07246135
NCT07196930
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions